FDA Approves New Formulation of Sjörgen’s Disease Treatment by Madaline Spencer| Published on: Oct 23, 2026

https://checkrare.com/fda-approves-new-formulation-of-sjorgens-disease-treatment/ The US Food and Drug Administration (FDA) has approved Evoxac (cevimeline HCI) oral solution to address dry mouth in patients with Sjögren’s disease (SjD). SjD is an autoimmune disorder that largely impacts secretory glands. It is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Hallmark symptoms include dry mouth and dry eyes, but the condition may cause skin, nose, and vaginal dryness. SjD may also affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain.